Pfizer Halts Late-Stage Trial of Potential Lymphoma Drug

For the second time this week, a major pharmaceutical company has pulled the plug on a trial testing a potential treatment for non-Hodgkin's lymphoma.

Earlier in the week, pharmaceutical giant Lilly halted the Phase III trial of a candidate for treating patients with diffuse large B-cell lymphoma.

Pfizer to test drug against other blood cancers

And now word comes from Pfizer Inc. saying that they, too, have halted a late-stage trial of an investigational drug for the treatment of aggressive non-Hodgkin's lymphoma after independent monitors of the trial concluded that the drug was unlikely to offer patients any survival benefits. This will not stop the company from testing the drug inotuzumab ozogamicin against other blood cancers, however.

In a statement released to the press, Pfizer's senior vice president of clinical development and medical affairs for its oncology business unit, Mace Rothenberg, said, "Hematologic cancers are a complex group of diseases with more than 70 different types of lymphomas, leukemias or myelomas that require unique treatment options."

No known safety issues with the drug

The trial had been testing inotuzumab in combination with the monoclonal antibody rituximab in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who were not candidates for intensive high-dose chemotherapy. This arm of the trial was being compared against two other arms – one that received rituximab plus Treanda and one that received rituximab and gemcitabine.

The monitors indicated that there were no safety problems with the drug, just inefficacy. Since conclusion of the trial would have begun the process of obtaining regulatory approval, and since monitors concluded that the combination was no better in terms of overall survival than the other two regimens, Pfizer decided to pull the plug.

It is not known which blood cancers the drug will be tested against next.

Source: Pfizer

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...